Related Experiment Video
Updated: Sep 25, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Multidrug resistance in prostate cancer
J P van Brussel1, G H J Mickisch
1Department of Urology, Erasmus Medical Center Rotterdam, The Netherlands.
Abstract:
Advanced hormone-refractory prostate cancer remains a therapeutic challenge, because all available pharmaceutical concepts have been ineffective in improving cancer-specific survival. Failure of chemotherapy may be caused by multidrug resistance (MDR) mechanisms protecting cancer cells against cytotoxic drugs, and the question arises whether prostate cancer is also using MDR principles resulting in resistance against chemotherapeutic agents. In consequence, an array of diverse pathways known to lead to MDR such as MDR1, MRPs, glutathione, and apoptosis have been examined and partially established at varying degrees in hormone-refractory prostate cancer. Thus, evidence keeps accumulating for the involvement of some MDR mechanisms in the chemoresistance of prostate cancer in vitro and in vivo. For some of them, e.g. MRP1, functional expression appears to be probable. This lends credit to the idea that reversal, circumvention, or overcoming of MDR pathways in advanced prostate cancer may be feasible and will lead to new avenues with improved treatment efficacy in otherwise intractable disease.
Insights
Multidrug resistance (MDR) mechanisms contribute to treatment failure in advanced hormone-refractory prostate cancer. Targeting these MDR pathways may improve therapeutic efficacy for this challenging disease.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Advanced hormone-refractory prostate cancer presents a significant therapeutic challenge.
- Current pharmaceutical treatments have not improved cancer-specific survival.
- Chemotherapy failure may stem from multidrug resistance (MDR) mechanisms in cancer cells.
Purpose of the Study:
- To investigate the involvement of MDR mechanisms in hormone-refractory prostate cancer.
- To explore whether prostate cancer utilizes MDR principles against chemotherapeutic agents.
Main Methods:
- Examination of diverse MDR pathways including MDR1, MRPs, glutathione, and apoptosis.
- Assessment of these mechanisms in hormone-refractory prostate cancer in vitro and in vivo.
Main Results:
- Evidence suggests the involvement of several MDR mechanisms in prostate cancer chemoresistance.
- Functional expression of some MDR mechanisms, like MRP1, appears probable.
- MDR pathways are partially established to varying degrees in this cancer type.
Conclusions:
- Multidrug resistance mechanisms play a role in the chemoresistance of hormone-refractory prostate cancer.
- Reversing, circumventing, or overcoming MDR pathways offers potential for improved treatment efficacy.
- Targeting MDR pathways may provide new therapeutic avenues for intractable prostate cancer.
More Related Videos
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance